Affiliation:
1. Groupe Hospitalier Pitié-Salpêtrière, Inserm U582, Association Institut de Myologie, IFR14, 47 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
2. Hôpital Trousseau, Service de Chirurgie Orthopédique 2, 37044 Tours Cedex 1, France; and: INSERM ESPRI EA 3855, Faculté de Médecine, Université François Rabelais, Tours, France.
Abstract
The progression of rheumatoid pathologies, degenerative diseases, traumatologies, and their cortege of increasing medical, social and economical needs, has mandated the development of tissue repair and engineering technologies in orthopedic medicine. Mesenchymal stem cells (MSCs) are multipotent cells that can be extracted from large and relatively easily accessible compartments of the body, especially the bone marrow, and such cells are able to differentiate into adipogenic, chondrogenic and osteogenic precursors. The concept of using MSCs to repair tissues has progressively evolved, and the goal of cell-mediated therapy is to prolong the natural physiological abilities of healing, or substitute them, when these are lacking, failing or progressing too slowly. In recent years, the first clinical trials on the utility of MSCs, with or without scaffolds and/or growth factors, have been initiated. In this review, the authors focus on findings from preclinical research, clinical trials and case reports involving bone and cartilage repairs. New perspectives are considered regarding uses of cell types, cell delivery approaches and growth factors. They also consider the stringent conditions, constraints and considerations necessary to take cell-mediated therapy from bench to bedside.
Subject
Embryology,Biomedical Engineering
Cited by
71 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献